P2Y12 - Wikipedia
The combination of a P2Y 12 inhibitor and aspirin, called dual antiplatelet treatment, remains the first-line treatment for acute coronary syndrome. A 2019 randomized trial suggested that prasugrel is superior to ticagrelor.
Antiplatelet medicines - P2Y12 inhibitors - MedlinePlus
2024年7月14日 · Antiplatelet drugs may be used to: Prevent heart attack or stroke for those with peripheral arterial disease (most often blockage of an artery in the leg). Clopidogrel (Plavix, generic) may be used in place of aspirin for people who have narrowing of the coronary arteries or who have had a stent inserted.
Comparative Review of Oral P2Y12 Inhibitors - PMC
Three oral P2Y 12 inhibitors are available: clopidogrel, prasugrel, and ticagrelor (Brilinta, AstraZeneca). Clopidogrel, the first P2Y 12 inhibitor, was the standard for DAPT until newer options became available.
International Expert Consensus on Switching Platelet P2Y12 …
2017年10月30日 · This expert consensus provides an overview of the pharmacology of P2Y 12 inhibitors, different modalities and definitions of switching, and available literature and recommendations for switching between P2Y 12 inhibitors.
P2Y12 inhibitors: pharmacologic mechanism and clinical relevance
It inhibits platelet aggregation by irreversibly blocking the adenosine diphosphate P2Y12 receptor. Ticagrelor, Cangrelor and Enilogrel represent the last generation of thienopyridines. This review is focused on the effects of adenosine diphosphate P2Y12 inhibitors.
Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in …
2020年5月29日 · This large-scale analysis on oral P2Y 12 inhibitors in ACS provides consistent findings of comparable anti-ischemic efficacy with the different potent platelet inhibitors, ticagrelor and prasugrel, in comparison with clopidogrel. Greater CV mortality reduction is observed with ticagrelor than with clopidogrel, whereas both agents carry a higher ...
P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: What Is …
The current paper focuses on the P2Y 12 receptor inhibitors and their pharmacogenetics and indications in patients with acute coronary syndromes or receiving percutaneous coronary interventions as well as the applicability of platelet function testing in this clinical context.
P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From …
Currently, the thienopyridine-based P2Y12 inhibitors, including clopidogrel and prasugrel, are utilized for the purpose of targeting ADP-mediated platelet activation and aggregation via the P2Y12 receptor.
New P2Y12 Inhibitors | Circulation - AHA/ASA Journals
2010年1月5日 · The P2Y12 antagonists, 2- methylthioadenosine 5′-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels.
P2Y12 Antagonists in Cardiovascular Disease—Finding the Best …
In addition to antiplatelet effects, recent evidence has suggested that P2Y 12 antagonists may have anti-inflammatory effects mediated by the indirect inhibition of platelet-leukocyte interactions or by the direct antagonism of P2Y 12 receptors expressed on macrophages.